159 related articles for article (PubMed ID: 18332865)
1. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
Steelman LS; Navolanic PM; Sokolosky ML; Taylor JR; Lehmann BD; Chappell WH; Abrams SL; Wong EW; Stadelman KM; Terrian DM; Leslie NR; Martelli AM; Stivala F; Libra M; Franklin RA; McCubrey JA
Oncogene; 2008 Jul; 27(29):4086-95. PubMed ID: 18332865
[TBL] [Abstract][Full Text] [Related]
2. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.
Chappell WH; Abrams SL; Franklin RA; LaHair MM; Montalto G; Cervello M; Martelli AM; Nicoletti F; Candido S; Libra M; Polesel J; Talamini R; Milella M; Tafuri A; Steelman LS; McCubrey JA
Cell Cycle; 2012 Dec; 11(23):4447-61. PubMed ID: 23159854
[TBL] [Abstract][Full Text] [Related]
3. PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo.
Chiang KC; Chen HY; Hsu SY; Pang JH; Wang SY; Hsu JT; Yeh TS; Chen LW; Kuo SF; Sun CC; Lee JM; Yeh CN; Juang HH
Drug Des Devel Ther; 2015; 9():4631-8. PubMed ID: 26316702
[TBL] [Abstract][Full Text] [Related]
4. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.
Scott KL; Kabbarah O; Liang MC; Ivanova E; Anagnostou V; Wu J; Dhakal S; Wu M; Chen S; Feinberg T; Huang J; Saci A; Widlund HR; Fisher DE; Xiao Y; Rimm DL; Protopopov A; Wong KK; Chin L
Nature; 2009 Jun; 459(7250):1085-90. PubMed ID: 19553991
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of cancers with loss of PTEN function.
Dillon LM; Miller TW
Curr Drug Targets; 2014 Jan; 15(1):65-79. PubMed ID: 24387334
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins.
Pioquinto-Avila E; González-Cruz AO; Solís-Estrada J; Hernández-Juarez J; Balderas-Rentería I; Villa-Cedillo SA; Pérez-Trujillo JJ; Arredondo-Espinoza E
Anticancer Res; 2024 Jun; 44(6):2567-2575. PubMed ID: 38821612
[TBL] [Abstract][Full Text] [Related]
7. The Association of PTEN Gene Mutations with the Breast Cancer Risk: A Systematic Review and Meta-analysis.
Yari K; Hakimi A; Mohammadi M; Ammari-Allahyari M; Salari N; Ghasemi H
Biochem Genet; 2023 Sep; ():. PubMed ID: 37658255
[TBL] [Abstract][Full Text] [Related]
8. DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis.
Cao S; Long X; Xiao L; Zhang P; Shen M; Chen F; Bao C; Zhong X; Luo T; Ye F
Front Oncol; 2024; 14():1356778. PubMed ID: 38549944
[TBL] [Abstract][Full Text] [Related]
9. Valproate modulates the activity of multidrug resistance efflux pumps, as a chemoresistance factor in gastric cancer cells.
Hosseini SA; Mirzaei SA; Kermani S; Yaghoobi H
Mol Biol Rep; 2024 Mar; 51(1):427. PubMed ID: 38498238
[TBL] [Abstract][Full Text] [Related]
10. Hijacking 5-Fluorouracil Chemoresistance in Triple Negative Breast Cancer via microRNAs-Loaded Chitosan Nanoparticles.
Fahmy SA; Mahdy NK; Mohamed AH; Mokhtar FA; Youness RA
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396746
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment.
Anderle N; Schäfer-Ruoff F; Staebler A; Kersten N; Koch A; Önder C; Keller AL; Liebscher S; Hartkopf A; Hahn M; Templin M; Brucker SY; Schenke-Layland K; Schmees C
J Exp Clin Cancer Res; 2023 Aug; 42(1):210. PubMed ID: 37596623
[TBL] [Abstract][Full Text] [Related]
12. Unpacking the Complexity of Epithelial Plasticity: From Master Regulator Transcription Factors to Non-Coding RNAs.
Waryah C; Alves E; Mazzieri R; Dolcetti R; Thompson EW; Redfern A; Blancafort P
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370762
[TBL] [Abstract][Full Text] [Related]
13. The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.
Rezaee M; Mohammadi F; Keshavarzmotamed A; Yahyazadeh S; Vakili O; Milasi YE; Veisi V; Dehmordi RM; Asadi S; Ghorbanhosseini SS; Rostami M; Alimohammadi M; Azadi A; Moussavi N; Asemi Z; Aminianfar A; Mirzaei H; Mafi A
Front Pharmacol; 2023; 14():1152672. PubMed ID: 37153758
[TBL] [Abstract][Full Text] [Related]
14. Genetic Characterization of Ovarian Tumor Tissues from Patients with Epithelial Ovarian Cancer in a Philippine Tertiary Hospital: A Descriptive Study.
Lintao RCV; Padua AJP; Nakura Y; Llamas-Clark EF; Yanagihara I
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1187-1197. PubMed ID: 37116140
[TBL] [Abstract][Full Text] [Related]
15. Phospho PTEN mediated dephosphorylation of mitotic kinase PLK1 and Aurora Kinase A prevents aneuploidy and preserves genomic stability.
Ghosh G; Misra S; Ray R; Chowdhury SG; Karmakar P
Med Oncol; 2023 Mar; 40(4):119. PubMed ID: 36930246
[TBL] [Abstract][Full Text] [Related]
16. A novel PTEN mutant caused by polymorphism in cis-regulatory elements is involved in chemosensitivity in breast cancer.
Wang J; Zhang S; Zhang J; Zhang Z; Ma Q; Fu W; Chen X; Zhao D; Zhao M; Di C; Xie X
Am J Cancer Res; 2023; 13(1):86-104. PubMed ID: 36777516
[TBL] [Abstract][Full Text] [Related]
17. Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics.
Subhan MA
RSC Adv; 2022 Nov; 12(51):32956-32978. PubMed ID: 36425155
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
[TBL] [Abstract][Full Text] [Related]
19. miRNA Pattern in Hypoxic Microenvironment of Kidney Cancer-Role of PTEN.
Majewska A; Brodaczewska K; Filipiak-Duliban A; Kajdasz A; Kieda C
Biomolecules; 2022 May; 12(5):. PubMed ID: 35625614
[TBL] [Abstract][Full Text] [Related]
20. Notch signaling in female cancers: a multifaceted node to overcome drug resistance.
Giuli MV; Mancusi A; Giuliani E; Screpanti I; Checquolo S
Cancer Drug Resist; 2021; 4(4):805-836. PubMed ID: 35582386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
